CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat central nervous system (CNS) diseases, today announced that Jeffrey Jonas, M.D., chief executive officer, is scheduled to present a company overview at the 2014 Leerink Global Healthcare Conference on Wednesday, February 12, 2014 at 2:40 p.m. ET. The conference is being held February 12-13, 2014 at the Waldorf Astoria in New York City.
About SAGE Therapeutics
SAGE Therapeutics is a neuroscience-focused company developing therapies to treat CNS specialty and orphan diseases. The company has identified several product opportunities with clear and accelerated paths to regulatory approval. SAGE’s initial pipeline includes programs in status epilepticus, anesthesia and orphan epilepsies such as Fragile X Syndrome, Dravet Syndrome and Rett Syndrome, where CNS drugs poorly address the areas of most urgent patient need and are often accompanied by considerable side effects. The company’s robust allosteric modulator chemistry platform – called the Positive and Negative Allosteric Modulator (PANAM) platform – has generated multiple new chemical entities that target the GABAA and NMDA pathways and have demonstrated promising preclinical data. SAGE Therapeutics is a private company launched in 2011 by a proven team of R&D leaders, renowned CNS experts and Third Rock Ventures. For more information, please visit www.sagerx.com.